54 related articles for article (PubMed ID: 24117654)
1. Impact of IL28B polymorphisms on 24-week telaprevir-based combination therapy for Asian chronic hepatitis C patients with hepatitis C virus genotype 1b.
Tsubota A; Shimada N; Atsukawa M; Abe H; Kato K; Ika M; Matsudaira H; Nagatsuma K; Matsuura T; Aizawa Y
J Gastroenterol Hepatol; 2014 Jan; 29(1):144-50. PubMed ID: 24117654
[TBL] [Abstract][Full Text] [Related]
2. Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy.
Hsu CS; Hsu SJ; Chen HC; Tseng TC; Liu CH; Niu WF; Jeng J; Liu CJ; Lai MY; Chen PJ; Kao JH; Chen DS
Proc Natl Acad Sci U S A; 2011 Mar; 108(9):3719-24. PubMed ID: 21321200
[TBL] [Abstract][Full Text] [Related]
3. Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamIC trial and real-life experience.
Waldenström J; Färkkilä M; Rembeck K; Norkrans G; Langeland N; Mørch K; Pedersen C; Rauning Buhl M; Nieminen U; Nuutinen H; Alsiö Å; Holmström L; Jungnelius R; Lund K; Rubensson A; Torell E; Westin J; Lagging M
Scand J Gastroenterol; 2016 Mar; 51(3):337-43. PubMed ID: 26418670
[TBL] [Abstract][Full Text] [Related]
4. Predictive factors for 24 weeks sustained virologic response (SVR24) and viral relapse in patients treated with simeprevir plus peginterferon and ribavirin.
Nakayama M; Kobayashi H; Fukushima K; Ishido M; Komada Y; Yoshizawa K
Hepatol Int; 2016 Jan; 10(1):158-68. PubMed ID: 26264253
[TBL] [Abstract][Full Text] [Related]
5. Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms.
Lagging M; Askarieh G; Negro F; Bibert S; Söderholm J; Westin J; Lindh M; Romero A; Missale G; Ferrari C; Neumann AU; Pawlotsky JM; Haagmans BL; Zeuzem S; Bochud PY; Hellstrand K;
PLoS One; 2011 Feb; 6(2):e17232. PubMed ID: 21390311
[TBL] [Abstract][Full Text] [Related]
6. Lambda interferon serum levels in patients with chronic hepatitis C virus infection according to their response to therapy with pegylated interferon and ribavirin.
Torres C; Brahm J; Venegas M
J Interferon Cytokine Res; 2014 Feb; 34(2):106-10. PubMed ID: 24070114
[TBL] [Abstract][Full Text] [Related]
7. Hepatic interferon-stimulated genes are differentially regulated in the liver of chronic hepatitis C patients with different interleukin-28B genotypes.
Honda M; Shirasaki T; Shimakami T; Sakai A; Horii R; Arai K; Yamashita T; Sakai Y; Yamashita T; Okada H; Murai K; Nakamura M; Mizukoshi E; Kaneko S
Hepatology; 2014 Mar; 59(3):828-38. PubMed ID: 24311440
[TBL] [Abstract][Full Text] [Related]
8. Predictors of early treatment discontinuation and severe anemia in a Brazilian cohort of hepatitis C patients treated with first-generation protease inhibitors.
Miotto N; Mendes LC; Zanaga LP; Goncales ES; Lazarini MS; Pedro MN; Goncales FL; Stucchi RS; Vigani AG
Braz J Med Biol Res; 2016 Jun; 49(7):. PubMed ID: 27356107
[TBL] [Abstract][Full Text] [Related]
9. First-generation protease inhibitor-triple therapy: SVR 24, safety, and predictors of response in a large single center cohort.
Werner CR; Franz C; Egetemeyr DP; Beck R; Malek NP; Lauer UM; Berg CP
Virol J; 2015 Mar; 12():37. PubMed ID: 25889921
[TBL] [Abstract][Full Text] [Related]
10. Cellular Mechanism for Impaired Hepatitis C Virus Clearance by Interferon Associated with IFNL3 Gene Polymorphisms Relates to Intrahepatic Interferon-λ Expression.
Ferraris P; Chandra PK; Panigrahi R; Aboulnasr F; Chava S; Kurt R; Pawlotsky JM; Wilkens L; Osterlund P; Hartmann R; Balart LA; Wu T; Dash S
Am J Pathol; 2016 Apr; 186(4):938-51. PubMed ID: 26896692
[TBL] [Abstract][Full Text] [Related]
11. Impact of specialty pharmacy on telaprevir-containing 3-drug hepatitis C regimen persistence.
Henderson RR; Visaria J; Bridges GG; Dorholt M; Levin RJ; Frazee SG
J Manag Care Spec Pharm; 2014 Dec; 20(12):1227-34. PubMed ID: 25443516
[TBL] [Abstract][Full Text] [Related]
12. Association of macrophage inhibitory factor -1 polymorphisms with antiviral efficacy of type 1b chronic hepatitis C.
Ye S; Chen Y; Lou X; Ye X; Yang X
Mol Cell Biochem; 2021 Jun; 476(6):2439-2447. PubMed ID: 33604810
[TBL] [Abstract][Full Text] [Related]
13. Using Stepwise Pharmacogenomics and Proteomics to Predict Hepatitis C Treatment Response in Difficult to Treat Patient Populations.
Naggie S; Clement M; Lusk S; Osinusi A; Himmel T; Lucas JE; Thompson WJ; Dubois L; Moseley MA; Clark PJ; Kottilil S; Patel K
Proteomics Clin Appl; 2019 May; 13(3):e1800006. PubMed ID: 30058111
[TBL] [Abstract][Full Text] [Related]
14. Gene polymorphisms of interleukin-28, p21-activated protein kinases 4, and response to interferon-α based therapy in Chinese patients with chronic hepatitis B.
Yu FX; Zhang XL; Wang YP; Ma N; DU H; Ma JM; Liu DW
Chin Med J (Engl); 2013; 126(9):1726-31. PubMed ID: 23652058
[TBL] [Abstract][Full Text] [Related]
15. Understanding triphasic HCV decline during treatment in the era of IL28B polymorphisms and direct acting antiviral agents via mathematical modeling.
Dahari H; Cotler SJ; Layden TJ; Perelson AS
J Hepatol; 2013 Apr; 58(4):840-2. PubMed ID: 23246507
[No Abstract] [Full Text] [Related]
16. Re-treatment of patients with chronic hepatitis C virus genotype 4 infection with pegylated interferon and ribavirin: a meta-analysis.
Zhang B; Nguyen NH; Yee BE; Yip B; Nguyen MH
BMJ Open Gastroenterol; 2015; 2(1):e000057. PubMed ID: 26629360
[TBL] [Abstract][Full Text] [Related]
17. Delayed Viral Clearance after 6-Week Treatment with Peginterferon Plus Ribavirin in a Patient with Chronic Hepatitis C Virus Genotype 1b.
Sato A; Ishii T; Adachi K; Takahashi H; Sano F; Matsumoto N
Case Rep Gastroenterol; 2016; 10(2):417-422. PubMed ID: 27721727
[TBL] [Abstract][Full Text] [Related]
18. Superior response to pegylated interferon and ribavirin in Asians with chronic hepatitis C.
Pattullo V; Heathcote EJ; Wong DK
Hepatol Int; 2010 Aug; 4(4):723-31. PubMed ID: 21286343
[TBL] [Abstract][Full Text] [Related]
19. Insights into the role of interferon lambda in hepatitis C virus infection.
Barth H
J Hepatol; 2011 May; 54(5):844-7. PubMed ID: 21145814
[No Abstract] [Full Text] [Related]
20. Reply: To PMID 23703931.
Noureddin M; Wright EC; Ghany MG
Hepatology; 2014 Apr; 59(4):1651. PubMed ID: 23959972
[No Abstract] [Full Text] [Related]
[Next] [New Search]
